Clinical trials: Kidney Transplant Recipient, active
Renal Transplantation
Effect of Probiotics on Immunosuppressive-drug-associated Diarrhea Among Renal Transplant Recipients
The goal of this pilot project is to 1) examine whether oral administration of probiotics are helpful in reducing immunosuppressive drugs-associated diarrhea and adhering to the required dose of immunosuppressive drugs and 2)…
- Trial name
- NCT06150287
- Testing
- Florajen Digestion
- Volunteers
- 70 people
- Sponsor
- State University of New York - Upstate Medical University
Renal Transplant Failure and Rejection
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease.
- Trial name
- MODERNIZE1 (NCT07508787)
- Testing
- Siplizumab, Rabbit anti-thymocyte globulin
- Where
- 14 sites in United States, Brazil and 1 more
- Volunteers
- 120 people
- Sponsor
- Nefro Avillion Clinical Development, LLC
Kidney Disease, Chronic, Transplant Recipient (Kidney)
Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus
This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective…
- Conditions
- Kidney Disease, Chronic, Transplant Recipient (Kidney), Immunosuppression
- Trial name
- TRANSPGx (NCT06701825)
- Testing
- Tacrolimus
- Where
- Spain
- Volunteers
- 114 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Rejection of Kidney Allograft
Blood Biomarkers in Pediatric Kidney Transplant Recipients
The objective of the proposed study is to assess whether a blood biomarker can be used to monitor the response to rejection treatment in pediatric kidney transplant recipients with biopsy-proven acute cellular or antibody…
- Trial name
- Omnigraf (NCT05477082)
- Testing
- Observational group
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Minnesota
Transplant Recipient (Kidney)
Immune Monitoring-Guided Individualized Tacrolimus Therapy in Renal Transplant Recipients: An Observational Study and PK/PD Modeling
This study aims to resolve the clinical limitation that therapeutic drug monitoring (TDM) alone cannot accurately reflect the net immune status after kidney transplantation.
- Trial name
- NCT07815938
- Testing
- No interventional treatment, only observational data collection without clinical drug adjustment
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Kidney Transplant Infection, Bloodstream Infection
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation
Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs).
- Conditions
- Kidney Transplant Infection, Bloodstream Infection, Kidney Transplant, Kidney Transplant Recipients
- Trial name
- PREDICT (NCT07407673)
- Testing
- Pivmecillinam
- Where
- 3 sites in Denmark
- Volunteers
- 180 people
- Sponsor
- Susanne Dam Nielsen, MD, DMSc
Highly Sensitized Prospective Kidney Transplant Recipients
Carfilzomib and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors.
- Trial name
- ADAPT (NCT05017545)
- Testing
- carfilzomib, belatacept, Bone marrow aspiration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.
Imlifidase is a recombinant cysteine protease derived from Streptococcus pyogenes and produced in Escherichia coli, which has the ability to cleave and degrade all human IgGs.
- Trial name
- ISKIA (NCT07379957)
- Where
- 20 sites in France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Bordeaux
Urinary Tract Infections, Kidney Transplant Rejection
PRObiotics for KIdney Transplantation
The goal of this clinical trial is to assess if dietary supplememtation with OMNi-BiOTiC® 41167 reduces the risk of urinary tract infections in kidney transplant recipients.
- Conditions
- Urinary Tract Infections, Kidney Transplant Rejection, Kidney Transplant Infection, Dysbiosis
- Trial name
- ProKiT (NCT06825117)
- Testing
- OMNi-BiOTiC® 41167
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- University Hospital, Udine, Italy
Transplant;Failure,Kidney, Transplant; Failure, Liver
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation?…
- Conditions
- Transplant;Failure,Kidney, Transplant; Failure, Liver, Adherence, Medication, Adherence, Patient
- Trial name
- NCT05613010
- Testing
- mHealth Messaging Intervention Group
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Johns Hopkins University
Cytomegalovirus (CMV) Infection, Kidney Transplant Recipient
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in…
- Trial name
- RESPECT-CMV (NCT07488481)
- Testing
- SYN002
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Kidney Transplant, Liver Transplant
Letermovir for R+ Study
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been…
- Trial name
- MISP CMV (NCT07706166)
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- University of Wisconsin, Madison
Liver Transplant Infection, Kidney Transplant Infection
Impact of Culture of Perfusion Fluid on Donor-derived Infection Management and Outcome in Liver and Kidney Transplant
This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible…
- Conditions
- Liver Transplant Infection, Kidney Transplant Infection, Liver Transplant, Kidney Transplant
- Trial name
- PREVENT (NCT07651137)
- Where
- Italy
- Volunteers
- 1,400 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Kidney Disease, Kidney Failure
Older Kidney Patient Optimisation Pretransplant
The goal of this clinical trial is to learn if a kidney transplant-specific comprehensive geriatric assessment (KT-CGA) can improve the way older adults are assessed for kidney transplantation.
- Conditions
- Kidney Disease, Kidney Failure, Frailty, Cognitive Impairment
- Trial name
- OK-POP (NCT07419945)
- Testing
- Kidney transplant-specific comprehensive geriatric assessment
- Volunteers
- 50 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Epstein-Barr Virus Infections
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
Epstein Barr virus infects over 90% of human population and persists during lifetime. After infecting B lymphocytes, EBV remains latent in memory B cells.
- Trial name
- REPLY (NCT04989491)
- Testing
- Rituximab, control group
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Interstitial Fibrosis, Kidney Transplant; Complications
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard…
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection
- Trial name
- NCT05285878
- Testing
- Fingolimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Urinary Tract Infections, Kidney Transplant; Complications
Double Voiding and Post-transplant UTI
Urinary tract infections (UTI) are common in kidney transplant recipients and are an important cause of illness and hospital admissions.
- Trial name
- NCT05711446
- Testing
- Double Voiding, Regular Voiding
- Where
- United States
- Volunteers
- 438 people
- Sponsor
- Weill Medical College of Cornell University
Kidney Transplant Recipient, Kidney Transplant; Complications
Vascular Complications After Kidney Transplantation
To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients…
- Conditions
- Kidney Transplant Recipient, Kidney Transplant; Complications, Transplant Renal Artery Stenosis, Renovascular Disease
- Trial name
- DAN-PTRAIII (NCT07531966)
- Testing
- Catheter-based angiography, Measurement of translesional pressure gradients, Intravascular ultrasound (IVUS)
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Kidney Transplant
Perceptions of Kidney Transplant Recipients Regarding the Role of Artificial Intelligence in Medicine
The AITX study is an international, multicenter survey exploring how kidney transplant recipients perceive artificial intelligence (AI) in medicine and, specifically, a system that predicts graft loss risk.
- Trial name
- AITX (NCT07600541)
- Where
- 2 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Transplant;Failure,Kidney, Transplant; Failure, Heart
EASE-SOT Pilot Study
Many transplant recipients may experience physical and emotional symptoms, such as anxiety, fatigue, sleep problems, pain, etc. Often, these symptoms are not reported or managed well, and can affect a patient's quality-of-life.
- Conditions
- Transplant;Failure,Kidney, Transplant; Failure, Heart, Transplant; Failure, Liver, Transplant; Failure, Pancreas
- Trial name
- NCT06396702
- Testing
- EASE-SOT
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto